Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 145 to 151 of 151 entries
Sorted by: Best Match Show Resources per page
Retro-tracheal parathyroid adenoma: A rare location of a common pathology.

Radiology case reports

Iyer S, Simon M, Tan C, Gesner L, Viggiano J, Chhabra S.
PMID: 32280399
Radiol Case Rep. 2020 Apr 05;15(6):672-674. doi: 10.1016/j.radcr.2020.03.003. eCollection 2020 Jun.

Ectopic parathyroid adenoma in the mediastinum has been reported in several publications; however, its location in the posterior mediastinum, especially a retro-tracheal location, has been rarely reported. We report a case of a 61-year-old patient who presented with clinical...

Cite
Iyer S, Simon M, Tan C, et al. Retro-tracheal parathyroid adenoma: A rare location of a common pathology. Radiol Case Rep. 2020;15(6):672-674doi: 10.1016/j.radcr.2020.03.003.
Iyer, S., Simon, M., Tan, C., Gesner, L., Viggiano, J., & Chhabra, S. (2020). Retro-tracheal parathyroid adenoma: A rare location of a common pathology. Radiology case reports, 15(6), 672-674. https://doi.org/10.1016/j.radcr.2020.03.003
Iyer, Sekhar, et al. "Retro-tracheal parathyroid adenoma: A rare location of a common pathology." Radiology case reports vol. 15,6 (2020): 672-674. doi: https://doi.org/10.1016/j.radcr.2020.03.003
Iyer S, Simon M, Tan C, Gesner L, Viggiano J, Chhabra S. Retro-tracheal parathyroid adenoma: A rare location of a common pathology. Radiol Case Rep. 2020 Apr 05;15(6):672-674. doi: 10.1016/j.radcr.2020.03.003. eCollection 2020 Jun. PMID: 32280399; PMCID: PMC7136598.
Copy Download .nbib Format: NLM
Patient Global Impression of Benefit-Risk (PGI-BR): Incorporating Patients' Views of Clinical Benefit-Risk into Assessment of New Medicines.

Drug safety

Eek D, Halling K, Flood E, Blowfield M, Meyers O, Venerus M, Paty J, Hermann R.
PMID: 34129206
Drug Saf. 2021 Oct;44(10):1059-1072. doi: 10.1007/s40264-021-01079-7. Epub 2021 Jun 15.

INTRODUCTION: There is a need to understand how patients assess perceived benefits and risks of treatments.OBJECTIVES: The study aimed to (i) elucidate how patients evaluate treatment experiences and (ii) develop a brief patient-reported outcome (PRO) instrument for use across...

Cite
Eek D, Halling K, Flood E, et al. Patient Global Impression of Benefit-Risk (PGI-BR): Incorporating Patients' Views of Clinical Benefit-Risk into Assessment of New Medicines. Drug Saf. 2021;44(10):1059-1072doi: 10.1007/s40264-021-01079-7.
Eek, D., Halling, K., Flood, E., Blowfield, M., Meyers, O., Venerus, M., Paty, J., & Hermann, R. (2021). Patient Global Impression of Benefit-Risk (PGI-BR): Incorporating Patients' Views of Clinical Benefit-Risk into Assessment of New Medicines. Drug safety, 44(10), 1059-1072. https://doi.org/10.1007/s40264-021-01079-7
Eek, Daniel, et al. "Patient Global Impression of Benefit-Risk (PGI-BR): Incorporating Patients' Views of Clinical Benefit-Risk into Assessment of New Medicines." Drug safety vol. 44,10 (2021): 1059-1072. doi: https://doi.org/10.1007/s40264-021-01079-7
Eek D, Halling K, Flood E, Blowfield M, Meyers O, Venerus M, Paty J, Hermann R. Patient Global Impression of Benefit-Risk (PGI-BR): Incorporating Patients' Views of Clinical Benefit-Risk into Assessment of New Medicines. Drug Saf. 2021 Oct;44(10):1059-1072. doi: 10.1007/s40264-021-01079-7. Epub 2021 Jun 15. PMID: 34129206; PMCID: PMC8473342.
Copy Download .nbib Format: NLM
Knowledge sharing in infection prevention in routine and outbreak situations: a survey of the Society for Healthcare Epidemiology of America Research Network.

Antimicrobial resistance and infection control

Sommerstein R, Geser S, Atkinson A, Tschan F, Morgan DJ, Marschall J.
PMID: 28804619
Antimicrob Resist Infect Control. 2017 Aug 08;6:79. doi: 10.1186/s13756-017-0237-5. eCollection 2017.

In this cross-sectional Society for Healthcare Epidemiology of America Research Network survey on knowledge sharing in infection prevention we identified a rudimentary understanding of how to communicate and share knowledge within healthcare institutions. Our data support the need of...

Cite
Sommerstein R, Geser S, Atkinson A, et al. Knowledge sharing in infection prevention in routine and outbreak situations: a survey of the Society for Healthcare Epidemiology of America Research Network. Antimicrob Resist Infect Control. 2017;6:79doi: 10.1186/s13756-017-0237-5.
Sommerstein, R., Geser, S., Atkinson, A., Tschan, F., Morgan, D. J., & Marschall, J. (2017). Knowledge sharing in infection prevention in routine and outbreak situations: a survey of the Society for Healthcare Epidemiology of America Research Network. Antimicrobial resistance and infection control, 679. https://doi.org/10.1186/s13756-017-0237-5
Sommerstein, Rami, et al. "Knowledge sharing in infection prevention in routine and outbreak situations: a survey of the Society for Healthcare Epidemiology of America Research Network." Antimicrobial resistance and infection control vol. 6 (2017): 79. doi: https://doi.org/10.1186/s13756-017-0237-5
Sommerstein R, Geser S, Atkinson A, Tschan F, Morgan DJ, Marschall J. Knowledge sharing in infection prevention in routine and outbreak situations: a survey of the Society for Healthcare Epidemiology of America Research Network. Antimicrob Resist Infect Control. 2017 Aug 08;6:79. doi: 10.1186/s13756-017-0237-5. eCollection 2017. PMID: 28804619; PMCID: PMC5549374.
Copy Download .nbib Format: NLM
Characterization of Biodegradable Microsphere-Hydrogel Ocular Drug Delivery System for Controlled and Extended Release of Ranibizumab.

Translational vision science & technology

Liu W, Borrell MA, Venerus DC, Mieler WF, Kang-Mieler JJ.
PMID: 30701127
Transl Vis Sci Technol. 2019 Jan 22;8(1):12. doi: 10.1167/tvst.8.1.12. eCollection 2019 Jan.

PURPOSE: To characterize a biodegradable microsphere-hydrogel drug delivery system (DDS) for controlled and extended release of ranibizumab.METHODS: The degradable microsphere-hydrogel DDSs were fabricated by suspending ranibizumab-loaded or blank poly(lactic-RESULTS: All DDS formulations investigated were injectable through a 28-gauge needle...

Cite
Liu W, Borrell MA, Venerus DC, et al. Characterization of Biodegradable Microsphere-Hydrogel Ocular Drug Delivery System for Controlled and Extended Release of Ranibizumab. Transl Vis Sci Technol. 2019;8(1):12doi: 10.1167/tvst.8.1.12.
Liu, W., Borrell, M. A., Venerus, D. C., Mieler, W. F., & Kang-Mieler, J. J. (2019). Characterization of Biodegradable Microsphere-Hydrogel Ocular Drug Delivery System for Controlled and Extended Release of Ranibizumab. Translational vision science & technology, 8(1), 12. https://doi.org/10.1167/tvst.8.1.12
Liu, Wenqiang, et al. "Characterization of Biodegradable Microsphere-Hydrogel Ocular Drug Delivery System for Controlled and Extended Release of Ranibizumab." Translational vision science & technology vol. 8,1 (2019): 12. doi: https://doi.org/10.1167/tvst.8.1.12
Liu W, Borrell MA, Venerus DC, Mieler WF, Kang-Mieler JJ. Characterization of Biodegradable Microsphere-Hydrogel Ocular Drug Delivery System for Controlled and Extended Release of Ranibizumab. Transl Vis Sci Technol. 2019 Jan 22;8(1):12. doi: 10.1167/tvst.8.1.12. eCollection 2019 Jan. PMID: 30701127; PMCID: PMC6350854.
Copy Download .nbib Format: NLM
Proton Bunch Self-Modulation in Plasma with Density Gradient.

Physical review letters

Braunmüller F, Nechaeva T, Adli E, Agnello R, Aladi M, Andrebe Y, Apsimon O, Apsimon R, Bachmann AM, Baistrukov MA, Batsch F, Bergamaschi M, Blanchard P, Burrows PN, Buttenschön B, Caldwell A, Chappell J, Chevallay E, Chung M, Cooke DA, Damerau H, Davut C, Demeter G, Deubner LH, Dexter A, Djotyan GP, Doebert S, Farmer J, Fasoli A, Fedosseev VN, Fiorito R, Fonseca RA, Friebel F, Furno I, Garolfi L, Gessner S, Goddard B, Gorgisyan I, Gorn AA, Granados E, Granetzny M, Grulke O, Gschwendtner E, Hafych V, Hartin A, Helm A, Henderson JR, Howling A, Hüther M, Jacquier R, Jolly S, Kargapolov IY, Kedves MÁ, Keeble F, Kelisani MD, Kim SY, Kraus F, Krupa M, Lefevre T, Li Y, Liang L, Liu S, Lopes N, Lotov KV, Martyanov M, Mazzoni S, Medina Godoy D, Minakov VA, Moody JT, Morales Guzmán PI, Moreira M, Muggli P, Panuganti H, Pardons A, Peña Asmus F, Perera A, Petrenko A, Pucek J, Pukhov A, Ráczkevi B, Ramjiawan RL, Rey S, Ruhl H, Saberi H, Schmitz O, Senes E, Sherwood P, Silva LO, Spitsyn RI, Tuev PV, Turner M, Velotti F, Verra L, Verzilov VA, Vieira J, Welsch CP, Williamson B, Wing M, Wolfenden J, Woolley B, Xia G, Zepp M, Zevi Della Porta G.
PMID: 33449727
Phys Rev Lett. 2020 Dec 31;125(26):264801. doi: 10.1103/PhysRevLett.125.264801.

We study experimentally the effect of linear plasma density gradients on the self-modulation of a 400 GeV proton bunch. Results show that a positive or negative gradient increases or decreases the number of microbunches and the relative charge per...

Cite
Braunmüller F, Nechaeva T, Adli E, et al. Proton Bunch Self-Modulation in Plasma with Density Gradient. Phys Rev Lett. 2020;125(26):264801doi: 10.1103/PhysRevLett.125.264801.
Braunmüller, F., Nechaeva, T., Adli, E., Agnello, R., Aladi, M., Andrebe, Y., Apsimon, O., Apsimon, R., Bachmann, A. M., Baistrukov, M. A., Batsch, F., Bergamaschi, M., Blanchard, P., Burrows, P. N., Buttenschön, B., Caldwell, A., Chappell, J., Chevallay, E., Chung, M., Cooke, D. A., Damerau, H., Davut, C., Demeter, G., Deubner, L. H., Dexter, A., Djotyan, G. P., Doebert, S., Farmer, J., Fasoli, A., Fedosseev, V. N., Fiorito, R., Fonseca, R. A., Friebel, F., Furno, I., Garolfi, L., Gessner, S., Goddard, B., Gorgisyan, I., Gorn, A. A., Granados, E., Granetzny, M., Grulke, O., Gschwendtner, E., Hafych, V., Hartin, A., Helm, A., Henderson, J. R., Howling, A., Hüther, M., Jacquier, R., Jolly, S., Kargapolov, I. Y., Kedves, M. �. �., Keeble, F., Kelisani, M. D., Kim, S. Y., Kraus, F., Krupa, M., Lefevre, T., Li, Y., Liang, L., Liu, S., Lopes, N., Lotov, K. V., Martyanov, M., Mazzoni, S., Medina Godoy, D., Minakov, V. A., Moody, J. T., Morales Guzmán, P. I., Moreira, M., Muggli, P., Panuganti, H., Pardons, A., Peña Asmus, F., Perera, A., Petrenko, A., Pucek, J., Pukhov, A., Ráczkevi, B., Ramjiawan, R. L., Rey, S., Ruhl, H., Saberi, H., Schmitz, O., Senes, E., Sherwood, P., Silva, L. O., Spitsyn, R. I., Tuev, P. V., Turner, M., Velotti, F., Verra, L., Verzilov, V. A., Vieira, J., Welsch, C. P., Williamson, B., Wing, M., Wolfenden, J., Woolley, B., Xia, G., Zepp, M., Zevi Della Porta, G. (2020). Proton Bunch Self-Modulation in Plasma with Density Gradient. Physical review letters, 125(26), 264801. https://doi.org/10.1103/PhysRevLett.125.264801
Braunmüller, F, et al. "Proton Bunch Self-Modulation in Plasma with Density Gradient." Physical review letters vol. 125,26 (2020): 264801. doi: https://doi.org/10.1103/PhysRevLett.125.264801
Braunmüller F, Nechaeva T, Adli E, Agnello R, Aladi M, Andrebe Y, Apsimon O, Apsimon R, Bachmann AM, Baistrukov MA, Batsch F, Bergamaschi M, Blanchard P, Burrows PN, Buttenschön B, Caldwell A, Chappell J, Chevallay E, Chung M, Cooke DA, Damerau H, Davut C, Demeter G, Deubner LH, Dexter A, Djotyan GP, Doebert S, Farmer J, Fasoli A, Fedosseev VN, Fiorito R, Fonseca RA, Friebel F, Furno I, Garolfi L, Gessner S, Goddard B, Gorgisyan I, Gorn AA, Granados E, Granetzny M, Grulke O, Gschwendtner E, Hafych V, Hartin A, Helm A, Henderson JR, Howling A, Hüther M, Jacquier R, Jolly S, Kargapolov IY, Kedves MÁ, Keeble F, Kelisani MD, Kim SY, Kraus F, Krupa M, Lefevre T, Li Y, Liang L, Liu S, Lopes N, Lotov KV, Martyanov M, Mazzoni S, Medina Godoy D, Minakov VA, Moody JT, Morales Guzmán PI, Moreira M, Muggli P, Panuganti H, Pardons A, Peña Asmus F, Perera A, Petrenko A, Pucek J, Pukhov A, Ráczkevi B, Ramjiawan RL, Rey S, Ruhl H, Saberi H, Schmitz O, Senes E, Sherwood P, Silva LO, Spitsyn RI, Tuev PV, Turner M, Velotti F, Verra L, Verzilov VA, Vieira J, Welsch CP, Williamson B, Wing M, Wolfenden J, Woolley B, Xia G, Zepp M, Zevi Della Porta G. Proton Bunch Self-Modulation in Plasma with Density Gradient. Phys Rev Lett. 2020 Dec 31;125(26):264801. doi: 10.1103/PhysRevLett.125.264801. PMID: 33449727.
Copy Download .nbib Format: NLM
Effectiveness of Clinical Decision Tools in Predicting Pulmonary Embolism.

Pulmonary medicine

Simon MA, Tan C, Hilden P, Gesner L, Julius B.
PMID: 33688434
Pulm Med. 2021 Feb 19;2021:8880893. doi: 10.1155/2021/8880893. eCollection 2021.

OBJECTIVE: The Wells criteria and revised Geneva score are two commonly used clinical decision tools (CDTs) developed to assist physicians in determining when computed tomographic angiograms (CTAs) should be performed to evaluate the high index of suspicion for pulmonary...

Cite
Simon MA, Tan C, Hilden P, et al. Effectiveness of Clinical Decision Tools in Predicting Pulmonary Embolism. Pulm Med. 2021;2021:8880893doi: 10.1155/2021/8880893.
Simon, M. A., Tan, C., Hilden, P., Gesner, L., & Julius, B. (2021). Effectiveness of Clinical Decision Tools in Predicting Pulmonary Embolism. Pulmonary medicine, 20218880893. https://doi.org/10.1155/2021/8880893
Simon, Michael A, et al. "Effectiveness of Clinical Decision Tools in Predicting Pulmonary Embolism." Pulmonary medicine vol. 2021 (2021): 8880893. doi: https://doi.org/10.1155/2021/8880893
Simon MA, Tan C, Hilden P, Gesner L, Julius B. Effectiveness of Clinical Decision Tools in Predicting Pulmonary Embolism. Pulm Med. 2021 Feb 19;2021:8880893. doi: 10.1155/2021/8880893. eCollection 2021. PMID: 33688434; PMCID: PMC7920730.
Copy Download .nbib Format: NLM
Efficacy and Safety of Ixekizumab in Patients with Psoriatic Arthritis and Inadequate Response to TNF Inhibitors: 3-Year Follow-Up (SPIRIT-P2).

Rheumatology and therapy

Orbai AM, Gratacós J, Turkiewicz A, Hall S, Dokoupilova E, Combe B, Nash P, Gallo G, Bertram CC, Gellett AM, Sprabery AT, Birt J, Macpherson L, Geneus VJ, Constantin A.
PMID: 33278016
Rheumatol Ther. 2021 Mar;8(1):199-217. doi: 10.1007/s40744-020-00261-0. Epub 2020 Dec 05.

PURPOSE: Ixekizumab is a high-affinity monoclonal antibody that selectively targets interleukin-17A. The objective of this study was to assess the long-term efficacy and safety (to week 156) of ixekizumab in patients with active psoriatic arthritis and inadequate response or...

Cite
Orbai AM, Gratacós J, Turkiewicz A, et al. Efficacy and Safety of Ixekizumab in Patients with Psoriatic Arthritis and Inadequate Response to TNF Inhibitors: 3-Year Follow-Up (SPIRIT-P2). Rheumatol Ther. 2020;8(1):199-217doi: 10.1007/s40744-020-00261-0.
Orbai, A. M., Gratacós, J., Turkiewicz, A., Hall, S., Dokoupilova, E., Combe, B., Nash, P., Gallo, G., Bertram, C. C., Gellett, A. M., Sprabery, A. T., Birt, J., Macpherson, L., Geneus, V. J., & Constantin, A. (2021). Efficacy and Safety of Ixekizumab in Patients with Psoriatic Arthritis and Inadequate Response to TNF Inhibitors: 3-Year Follow-Up (SPIRIT-P2). Rheumatology and therapy, 8(1), 199-217. https://doi.org/10.1007/s40744-020-00261-0
Orbai, Ana-Maria, et al. "Efficacy and Safety of Ixekizumab in Patients with Psoriatic Arthritis and Inadequate Response to TNF Inhibitors: 3-Year Follow-Up (SPIRIT-P2)." Rheumatology and therapy vol. 8,1 (2021): 199-217. doi: https://doi.org/10.1007/s40744-020-00261-0
Orbai AM, Gratacós J, Turkiewicz A, Hall S, Dokoupilova E, Combe B, Nash P, Gallo G, Bertram CC, Gellett AM, Sprabery AT, Birt J, Macpherson L, Geneus VJ, Constantin A. Efficacy and Safety of Ixekizumab in Patients with Psoriatic Arthritis and Inadequate Response to TNF Inhibitors: 3-Year Follow-Up (SPIRIT-P2). Rheumatol Ther. 2021 Mar;8(1):199-217. doi: 10.1007/s40744-020-00261-0. Epub 2020 Dec 05. PMID: 33278016; PMCID: PMC7991062.
Copy Download .nbib Format: NLM
Showing 145 to 151 of 151 entries